Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
111, Inc. (NASDAQ: YI) announced a successful new capital injection of RMB515 million (approximately US$78.75 million) for its subsidiary, Yao Fang Shanghai, aimed at expanding its digital healthcare services in China. This follows a previous funding round of RMB419.82 million, totaling RMB934.82 million (approximately US$142.84 million) raised to date. The investment also supports a proposed listing on the Shanghai Stock Exchange's STAR Market by June 30, 2023. Investors include notable firms such as SAIF Partners and Huasai Fund.
111, Inc. (NASDAQ: YI) reported robust financial growth for Q3 2020, with net revenues reaching RMB2.36 billion (US$348.0 million), up 112.8% YoY. Operating expenses increased 28.2% to RMB212.1 million, representing 9.0% of revenues. The number of pharmacies served climbed to over 300,000, covering 57% of China’s pharmacies. B2B revenue soared to RMB2.2 billion, while non-GAAP net loss narrowed to 4%. The company expects Q4 revenues between RMB2.44 billion and RMB2.56 billion, indicating year-over-year growth of approximately 81% to 90%.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for Q3 2020 on November 19, 2020, before U.S. market opens. An earnings conference call is scheduled for 7:30 AM ET on the same day. Participants must register in advance to receive dial-in details. The company, a major digital healthcare platform in China, connects patients with healthcare products and services through its online retail pharmacy, 1 Drugstore, and its offline virtual pharmacy network. Additionally, it provides online healthcare services via 1 Clinic and wholesale services through 1 Drug Mall.
On September 24, 111, Inc. formed a strategic partnership with Bayer Healthcare to enhance drug commercialization in China, particularly in tier 3-6 cities. This collaboration will leverage 111's omni-channel platform to improve drug accessibility and patient education for chronic disease management. The partnership aims to develop a digital content portal to facilitate online pharmacist training and patient services. Co-COO Wang Haihui expressed confidence in transforming healthcare delivery, while Bayer's Zhang Jingchuan highlighted the mutually beneficial nature of their expertise.
On September 24, 111, Inc. (NASDAQ: YI) established a strategic partnership with Hainan Huluwa Pharmaceutical Group in Shanghai. This collaboration aims to enhance the market reach of Huluwa's pediatric healthcare products using 111's integrated smart supply chains. Both companies will leverage digital technologies and AI to improve marketing and services. The partnership seeks to provide better access to safe pediatric medications in China, impacting millions of children.
On September 24, 2020, 111, Inc. (YI) signed a strategic partnership with Guangzhou Xiangxue Pharmaceutical to enhance the 'Internet + Medicine' model in China's traditional medicine sector. This collaboration will allow 111 to act as an omni-channel commercialization partner for Xiangxue Pharmaceutical, leveraging its Smart Supply Chain and digital marketing capabilities. With a vast network covering 280,000 pharmacies in China, 111 aims to increase the reach of Xiangxue's traditional medicine products, enhancing patient access and operational efficiency.
On September 24, 111, Inc. (NASDAQ: YI) signed a strategic partnership with Shanghai Uniondrug Information Technology to enhance commercial insurance and oncology drug retail services. This collaboration aims to improve healthcare access by integrating pharmaceutical companies and insurers, ultimately reducing medication costs for patients. Dr. YU Gang emphasized the market opportunities arising from government reforms in China's healthcare sector. The partnership also focuses on creating an integrated healthcare ecosystem to benefit doctors, pharmacies, and patients.
On September 24, 2020, 111, Inc. (NASDAQ: YI) hosted its 3rd annual China Online Healthcare Summit in Shanghai, focusing on healthcare digitalization. The event gathered around 600 industry leaders and executives, discussing challenges posed by new Chinese regulations and innovations like 111's omni-channel platform. The company announced strategic partnerships with notable firms including Novartis and Bayer. Dr. Gang YU predicts that digital healthcare will surpass real estate and automotive industries in China over the next decade, highlighting 111's role in enhancing healthcare access through technology.
On August 25, 111, Inc. (Nasdaq: YI) and Guangzhou Baiyunshan Pharmaceutical Sales Co., Ltd. signed a strategic cooperation agreement in Shanghai. This partnership aims to innovate digital medicine and enhance the distribution of Baiyunshan's medical products in both online and offline markets. The collaboration will also leverage big data, digital marketing, and patient services to create an effective value chain. This initiative reflects the increasing importance of digital healthcare, especially amid the ongoing COVID-19 pandemic, and aims to improve patient access to medical services in China.
111, Inc. (NASDAQ: YI) reported second quarter 2020 net revenues of RMB1.62 billion (US$229.6 million), marking a 93.5% increase year-over-year. Operating expenses rose to RMB177.5 million (US$25.1 million), but represented a smaller proportion of revenues at 10.9% versus 17.0% last year. The company’s non-GAAP net loss narrowed to 4.9% of revenue, down from 10.1% year-over-year. Notable growth was seen in the B2B segment, with 113.7% revenue growth. The upcoming third quarter outlook projects revenues between RMB2 billion and RMB2.17 billion, indicating continued expansion.